GLR1061 / Gan & Lee Pharma - LARVOL DELTA

Preclinical characterization of GLR1061, a B7H3-targeted ADC with a novel DNA topoisomerase I inhibitor, demonstrated superior bystander effect to overcome tumor heterogeneity (AACR 2025) - "B7H3-targeted antibody-drug conjugates (ADCs), such as DS7300, have shown positive clinical efficacy in small cell lung cancer, squamous non-small cell lung cancer, metastatic castration-resistant prostate cancer. In a preclinical repeated-dose toxicology study in mice, GLR1061 showed good tolerability and reversible toxicity. Overall, GLR1061 demonstrated excellent specificity, efficacy, and safety as a next-generation therapy for the treatment of B7H3-positive tumors."

Heterogeneity • Preclinical • Breast Cancer • Castration-Resistant Prostate Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD276